A new topical medication, Clascoterone, shows promise for hairloss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
The conversation discusses the potential of new hairloss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.
A user experienced continuous hair shedding for 13 months after starting finasteride, suspecting it might cause chronic telogen effluvium, and considered switching to dutasteride or stopping medication. Other users suggested that finasteride doesn't cause hairloss, recommending dutasteride for more aggressive hairloss, while some advised against stopping medication.
The user is experiencing severe hair shedding after using RU58841, stemoxydine, and minoxidil, and has stopped using finasteride due to side effects. They hope the shedding is temporary and will lead to regrowth.
A user is experiencing hairloss and is using Morr F 5% Minoxidil, Finasteride Lipid Solution, ketoconazole shampoo, and biotin tablets. They seek advice on the correct application method and hair partitioning.
A 32-year-old male shares his 5-year progress using finasteride, minoxidil, RU58841, and ketoconazole for hairloss. Despite consistent use, he feels his hair isn't as thick as before and is concerned about continued shedding and hairline miniaturization.
The user experienced hairloss diagnosed as chronic Telogen Effluvium and male pattern baldness, treated with finasteride and minoxidil, later switching to dutasteride due to side effects but with limited success. The user plans to return to finasteride due to side effects from dutasteride, while others suggest maintaining consistent treatment and considering additional options like oral minoxidil and lifestyle changes.
The user is considering using Tacrolimus Solution and topical Dutasteride to avoid shedding caused by Minoxidil, which they fear may lead to facial side effects. They are also concerned about scalp sensitivity and are exploring different treatment bases to manage seborrheic dermatitis.